Keywords
How to Cite
Abstract
The systemic radionuclide therapy with bone affinity substances is an effective therapy in bone palliative treatment. Studies with radiolabeled Bisphosphonate or strontium-89 show reduction of pain in 70-80% and about 20% of treated patients are pain-free. The generator product rhenium-188 represents an interesting radionuclide for bone pain palliation. It is readily available and with appropriate patient numbers is very cost-effective. Radiopharmaceuticals with Re-188 show a comparable effectiveness in bone pain palliation and bone marrow toxicity as the other known radioactive Bisphosphonate. Repeat courses of treatment with rhenium-188 HEDP even a slightly increased survival could be observed. Using therapy with alpha emitters Radium-223 in prostate cancer patients with bone metastases there was observed a prolongation of survival by 3,6 months compared with placebo. Two drugs are created in Russia on the basis of Re-188. Phosphoren is an analog of Re-188-HEDP. It showed properties similar to them in clinical studies. Complex Re-188-zoledronic acid (Zoleren) is a unique development that combines the therapeutic effect of zoledronic acid and Re-188.References
Кочетова Т. Ю., Крылов В. В., Смолярчук М. Я. и др. 188Rе-золедроновая кислота - новый отечественный радиофармпрепарат: первый клинический опыт // Поволжский онкол. Вестн. - 2014. -№ 3. -С. 41-46
Крылов B. В., Кочетова Т. Ю. Радионуклидная терапия 188Re-гидроксиэтилидендифосфонатом в лечении больных с метастазами в кости // Мед. радиол. и радиацион. безопасность. -2014. -№ 6. - С. 54 - 63.
Крылов В. В., Кочетова Т. Ю., Волознев Л. В. Радионуклидная терапия при метастазах в кости. Новые возможности // Вопр. онкол. - 2015. - Т. 61. -№ 1. - С. 14 - 19.
Петриев В. М., Сморызанова О. А., Скворцов В. Г. Изу чение фармакокинетики 188RЕ-КNА-гидроксиэтили дендифосфоната в организме интактных крыс // Вопр. биологич., мед. и фармацевт. химии. -2007. - № 2. -С. 11-16.
Aihara T, Kim Y, Takatsuka Y. Phase II study of weekly docetaxel in patients with metastatic breast cancer // Ann Oncol. - 2002. - Vol. 13 (2). - P. 286-292.
Berthold DR, Pond GR, Soban F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study // J Clin Oncol. - 2008. - Vol. 10 (26). - P. 242-245.
Biersack HJ, Palmedo H, Andris A. et al. Palliation and survival after repeated (188)Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis // J Nucl Med. - 2011. - Vol. 52 (11). - P 1721-1726.
Body JJ. Metastatic bone disease: clinical and therapeutic aspects. Bone. 1992;13 Suppl 1:S57-62.
Chiang PH, Wang HC, Lai YL. et al. Zoledronic acid treatment for cancerous bone metastases: a phase IV study in Taiwan // J Cancer Res Ther. - 2013. - Vol. 9 (4). - P. 653-659.
Chinnaiyan P, Huang S, Armstrong E, Harari PM. Radiosensitization following EGFR signaling inhibition by erlotinib (Tarceva) // Int J Radiat Oncol Biol Phys. - 2003. - Vol. 57 (2 Suppl). - S 294.
Cortes JE, Pazdur R. Docetaxel // J Clin Oncol. - 1995. - Vol. 13 (10). - P. 2643-2655.
Dafermou AF, Colamussi PF, Giganti M. F. et al. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer // Eur J Nucl Med. - 2001. - Vol. 28 (7). - P. 788-798.
de Bono JS, Logothetis CJ, Molina A. et al. Abiraterone and increased survival in metastatic prostate cancer // N Engl J Med. - 2011. - Vol. 26 (364). - P. 1995-2005.
Enrique O, Zhonyun P, Prma EP et al. Efficacy and toxicity of Sm-153 EDTMP in the palliative treatment of painful bone metastases // World J Nucl Med. - 2002. - Vol. 1. - P 21-27.
Ernst DS, Tannock IF, Winquist EW. et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain // J Clin Oncol. - 2003. - Vol. 21 (17). - P. 3335-3342.
Esteva FJ, Valero V, Pusztai L. et al. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond // Oncologist. - 2001. - Vol. 6 (2). - P 133-146.
Fettich J, Padhy AK, Nair N, Morales R. Comparative clinical efficacy and safety of phosphorus and strontium-89 in the palliative treatment of metastatic bone apin: results of an IAEA coordination research project // W J Nucl Med. - 2003. - Vol. 2. - P 226-231.
Fizazi K, Yang J, Peleg S. et al. Prostate cancer cells-osteoblast interaction shifts expression of growth/survivalrelated genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts // Clin Cancer Res. -2003. - Vol. 9 (7). - P. 2587-2597.
Friedell HL, Storaasli JP The use of radioactive phosphorus in treatment of carcinoma of the breast with widespread metastasis in bone // AJR. - 1950. - Vol. 64. - P. 559575.
Graham C, Bond SS, Gerkovich MM, Cook MR. Use of the McGill pain questionnaire in the assessment of cancer pain: replicability and consistency // Pain. - 1980. - Vol. 8 (3). -0 P. 377-387.
Harari PM, Huang SM. Epidermal growth factor receptor modulation of radiation response: preclinical and clinical development // Semin Radiat Oncol. - 2002. - Vol. 12 (3). - P. 21-26.
Haris JR, Hellmann S, Henderson IC. Breast disease. In: I H, editor. Chemotherapy Metastatic disease. 2nd: Lippincott Company, Philadelphia, PA, USA; 1991.
Hortobagyi GN, Gutterman JU, Blumenschein GR. et al. Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG // Cancer. - 1979. - Vol. 44 (5). - P 1955-1962.
Kakonen SM, Selander KS, Chirgwin JM. et al. Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways // J Biol Chem. - 2002. - Vol. 277 (27). - P. 24571-24578.
Knapp FF, Kropp J, Liepe K. Rhenium-188 generator-based radiopharmaceuticals for therapy. In: Baum RP, editor. Theraeutic Nulear Medicine. -Srpinger, Heidelberg -2014. -P 51-82.
Kraeber-Bodere F, Campion L, Rousseau C. et al. Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement // Eur J Nucl Med. - 2000. - Vol. 27 (10). - P 1487-1493.
Krylov V., Kochetova T., Smolyarchuk M. et al. Evaluation of 188Re-KHEDP (Phosphoren) for palliative treatment in patients with bone metastases // World Journal of Nuclear Medicine. - 2013. -Vol. 12. -P. 255 - 256.
Lam MGH, Bosma TB, van Rijk PP, Zonneberg BA. 188Re-HEDP combined with capecitabine in hromon-refreactory prostate cancer patients with bone metastases: a phase I safety and toxicity study // Eur J Nucl Med Mol Imaging. - 2009. - Vol. 36. - P 1425-1433.
Lange R, de Klerk JM, Bloemendal HJ. et al. Drug composition matters: the influence of carrier concentration on the radiochemical purity, hydroxyapatite affinity and in-vivo bone accumulation of the therapeutic radiopharmaceutical 188Rhenium-HEDP // Nucl Med Biol. - 2015. - Vol. 42 (5). - P. 465-469.
Li S, Liu J, Zhang H. et al. Rhenium-188 HEDP to treat painful bone metastases // Clin Nucl Med. - 2001. - Vol. 26 (11). - P 919-922.
Liepe K, Kotzerke J. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases // Nucl Med Commun. - 2007. - Vol. 28. - P. 623-630.
Liepe K, Kotzerke J. Internal radiotherapy of painful bone metastases // Methods. - 2011. -Vol. 55 (3). - P. 258270.
Liepe K. Radium-223 chloride in bone pain treatment of prostate cancer // Nuklearmediziner. - 2015. - Vol. 38 (2). - P 131-137.
Liepe K, Runge R, Kotzerke J. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain // J Cancer Res Clin Oncol. - 2005. - Vol. 131 (1). - P. 60-66.
Liepe K, Runge R, Kotzerke J. Systemic radionuclide therapy in pain palliation // Am J Hosp Palliat Care. -2005. - Vol. 22 (6). - P. 457-464.
Liepe K, Geidel HH, Bergmann R. et al. Autoradiographic studies of rhenium-188-hydroxyethylidine diphosphonate in normal skeleton and osteoblastic bone metastases in a rat model of metastatic prostate cancer // Nucl Med Commun. - 2009. - Vol. 30 (9). - P. 693-699.
Liepe K, Hliscs R, Kropp J. et al. Rhenium-188-HEDP in the palliative treatment of bone metastases // Cancer Biother Radiopharm. - 2000. - Vol. 15 (3). - P. 261-265.
Liepe K, Kropp J, Runge R, Kotzerke J. Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases // Br J Cancer. - 2003. - Vol. 89 (4). - P. 625-629.
Liepe K, Franke WG, Kropp J. et al. Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases // Nuklearmedizin. - 2000. - Vol. 39 (6). - P. 146-151.
Liepe K, Hliscs R, Kropp J. et al. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases // J Nucl Med. - 2003. - Vol. 44 (6). - P. 953-960.
Liepe K, Geidel H, Haase M. et al. New model for the induction of osteoblastic bone metastases in rat // Anticancer Res. - 2005. - Vol. 25 (2A). - P. 1067-1073.
Lin A, Ray ME. Targeted and systemic radiotherapy in the treatment of bone metastasis // Cancer Metastasis Rev. - 2006. - 25 (4). - P. 669-675.
Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities // Nat Rev Cancer. - 2002. - Vol. 2 (8). - P. 584-593.
Nair N. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases // J Nucl Med. - 1999. - Vol. 40 (2). - P. 256-261.
Nielsen OS, Munro AJ, Tannock IF. Bone metastases: pathophysiology and management policy // J Clin Oncol. - 1991. - Vol. 9 (3). - P. 509-524.
Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer // J Urol. - 2002. - Vol. 168 (3). -P. 1005-1007.
O’Sullivan JM, Norman AR, McCready VR. et al. A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone // Eur J Nucl Med Mol Imaging. - 2006. - Vol. 33 (9). - P. 1055-1061.
Palmedo H, Guhlke S, Bender H et al. Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases // Eur J Nucl Med. - 2000. - Vol. 27 (2). - P. 123-130.
Palmedo H, Manka-Waluch A, Albers P. et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate // J Clin Oncol. - 2003. - vol. 21 (15). - P. 2869-2875.
Paridaens R, Biganzoli L, Bruning P. et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over // J Clin Oncol. - 2000. - Vol. 18 (4). - P. 724-733.
Pecher P. Biological investigation with radioactive calcium and strontium. Preliminary report on the use of radioactive strontium in the treatment of metastatic bone cancer // University of California Publications in Pharmacology. -1942. - Vol. 2. - P. 117-149.
Pons F, Herranz R, Garcia A. et al. Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer // Eur J NuclMed. - 1997. -Vol. 24 (10). - P. 1210-1214.
Porter AT, McEwan AJ. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial // Semin Oncol. - 1993. - Vol. 20 (2). - P. 38-43.
Serafini AN. Current status of systemic intravenous radiopharmaceuticals for the treatment of painful metastatic bone disease // Int J Radiat Oncol Biol Phys. - 1994. - Vol. 30 (5). - P. 1187-1194.
Shipman CM, Rogers MJ, Apperley J et al. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity // Br J Haematol. - 1997. - Vol. 98 (3). - P. 665-672.
Sledge GW, Neuberg D, Bernardo P. et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193) // J Clin Oncol. - 2003. - Vol. 21 (4). - P. 588-592.
Smeland S, Erikstein B, Aas M. et al. Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study // Int J Radiat Oncol Biol Phys. - 2003. - Vol. 56 (5).
Smolyarchuk M., Davydov G., Aleksandrova A. et al. Evaluation of the Pharmacokinetics of 188Re-HEDP and 99mTc-HDP in Humans // World Journal of Nuclear Medicine. - 2013. -Vol. 12. -P. 228 - 229.
Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine // J Nucl Med. - 1996. - Vol. 37 (3). - P. 538-546.
ter Heine R, Lange R, Breukels OB. et al. Bench to bedside development of GMP grade Rhenium-188-HEDP, a radiopharmaceutical for targeted treatment of painful bone metastases // Int J Pharm. - 2014. - 25 (1). - P. 317-324.
Tu SM, Millikan RE, Mengistu B. et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial // Lancet. -2001. - Vol. 357 (9253). - P. 336-341.
von Moos R, Sternberg C, Body JJ, Bokemeyer C. Reducing the burden of bone metastases: current concepts and treatment options // Support Care Cancer. - 2013. - Vol. 24 (6). - P. 1773-1783.
Weinfurt KP, Anstrom KJ, Castel LD. Et al. Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer // Ann Oncol. - 2006. - Vol. 17 (6). - P. 986-989.
World Health Organization. Cancer Pain Relief and Palliative Care: Report of a WHO Expert Committee. Geneva, Switzerland: World Health Organization. 1990.
Zhuikov BL. Production of medical radionuclides in Russia: Status and future-a review // Appl Radiat Isot. -2014. - Vol. 84. - P. 48-56.
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...